A Phase 1b Study of HB-502 and HB-501 in People With HIV

Study Description

A Study Evaluating the Safety and Effectiveness of an Experimental Treatment for HIV

Study Details

Registry ID:

NCT06430905

Conditions:

Human Immunodeficiency Virus (HIV) Infection

Phase:

Phase 1

Target Enrollment:

30 participants

Start Date:

July 1, 2024

Age Range:

18–65 years

Healthy Volunteers:

No

Study Locations (6 sites)

• Beth Israel Deaconness Medical Center
  Boston, MassachusettsUnited States, United States
• Brigham and Women´s Hospital
  Boston, MassachusettsUnited States, United States
• Beth Israel Deaconness Medical Center (BIDMC)
  Boston, MassachusettsUnited States, United States
• Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania
  Philadelphia, PennsylvaniaUnited States, United States
• Orlando Immunology Center (OIC)
  Orlando, FloridaUnited States, United States
• The Hope Clinic at Emory University
  Decatur, GeorgiaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →